Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biyan Qingdu granule for prevention and treatment of acute nasal and oral radiation injury in nasopharyngeal carcinoma
ChiCTR2200060900Phase 4Not yet recruiting
- Sponsor
- Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 4 trial of Biyan Qingdu Granula in nasopharyngeal carcinoma (NPC), Radiotherapy-induced mucositis (RIOM) and Nasal mucosal injury (3 arms), sponsored by Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Symptom grading of nasal secretions and WHO classification of oral mucosal injury. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
Biyan Qingdu Granula
03
Conditions
nasopharyngeal carcinoma (NPC)Radiotherapy-induced mucositis (RIOM)Nasal mucosal injury
Beyond the preview
Go deeper on ChiCTR2200060900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060900.